Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B, Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI (Axitinib Implant) for Intravitreal Injection in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy

NCT05695417 is registered in ClinicalTrials.gov with Ocular Therapeutix, Inc. as lead sponsor.

NCT NCT05695417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05695417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B, Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI (Axitinib Implant) for Intravitreal Injection in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
Lead sponsor
Ocular Therapeutix, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
January 15, 2023
Completion date
December 31, 2024
Enrollment
21 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

non-proliferative diabetic retinopathy